MODIFICATION
68 -- Stereochemistry of lead compounds and Synthesis of lead compounds
- Notice Date
- 1/11/2016
- Notice Type
- Modification/Amendment
- NAICS
- 325199
— All Other Basic Organic Chemical Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Institute on Drug Abuse, 6001 Executive Boulevard, Room 4211 - MSC 9559, Bethesda, Maryland, 20892, United States
- ZIP Code
- 20892
- Solicitation Number
- HHS-NIH-NIDA-SSSA-CSS-2016-23
- Archive Date
- 2/9/2016
- Point of Contact
- Rodney E. Brooks, Phone: 3014020751
- E-Mail Address
-
rodney.brooks@nih.gov
(rodney.brooks@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- The purpose of this amendment is the change the response date from January 25, 2016 to January 22, 2016. Combined Synopsis / Solicitation Title: Stereochemistry of lead compounds and Synthesis of lead compounds (i)This is a combined synopsis-solicitation for commercial items or services prepared in accordance with the format in Subpart 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested and a written solicitation will not be issued. (ii)The solicitation number is HHS-NIH-NIDA-SSSA-CSS-2016-23 and the solicitation is issued as a request for proposal (RFP). This acquisition is for a commercial item or service and is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13-Simplified Acquisition Procedures; FAR Subpart 13.5-Test Program for Certain Commercial Items; and FAR Part 12-Acquisition of Commercial Items, and is not expected to exceed the simplified acquisition threshold. (iii)The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular 2005-85-1/01-04-2016. Business size standard: other than small with 1,000 employees. (iv)A notice regarding any set-aside restrictions, the associated NAICS code 325199- Chemical Manufacturing - All other basic organic chemical Manufacturing (v)Stereochemistry of lead compounds and Synthesis of lead compounds (vi)Background The National Institutes of Health (NIH) is the nation's leading medical research agency and the primary Federal agency whose mission is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability, conducting, supporting and making medical discoveries that improve people's health and save lives. The National Center for Advancing Translational Sciences (NCATS) is a translational science center that prides itself on its tremendously productive pipeline and is innovative in a number of ways. First, our quantitative high throughput screening (qHTS) paradigm, which tests all compounds at multiple concentrations in the primary screen, is unique. Second, NCATS is distinctive in its focus on collaboration with outside investigators to produce high-quality chemical probes to define and assess new biology. This focus is reflected in our unprecedented outreach program, which reaches hundreds of potential new investigators every year, and accounts for much of the new science being done at the NCATS. Third, NCATS is uniquely focused on new technologies and paradigms to improve the process of translational science, typified by qHTS, our informatics platform, our utilization of structural biology to accelerate probe development, development of new synthetic and analytical chemistry paradigms. Ultimately, NCATS brings together a diverse range of scientists, including medicinal chemists, biologists, toxicologists, and engineers, in order to ultimately translate basic science into real products and services that help improve people's lives. Included in this process is the development of unique biological discoveries into potential pharmaceuticals which can greatly assist patients. Purpose The purpose of this requirement is to purchase the Synthesis of 10.0 g of 7-bromo-6-chloro-3-(3-(4-chloro-3,5-dimethylphenoxy)propyl)-2-(trifluoromethyl)-1H-indole (CAS: 1666138-82-4). Scope of Work Independently and not as an agent of the Federal Government, the contractor shall provide 10.0 grams of (7-bromo-6-chloro-3-(3-(4-chloro-3,5-dimethylphenoxy)propyl)-2-(trifluoromethyl)-1H-indole (CAS: 1666138-82-4). The material will be provided with purity exceeding 95%. The Contractor shall also provide 100.0 grams of (R)-norketamine. (R)-Norketamine has the IUPAC name of (R)-2-amino-2-(2-chlorophenyl)cyclohexanone, with a CAS number of 83777-64-4. The (R)-norktamine will be provided with purity and enantiomeric excess exceeding 95%. The (R)-norketamine will be provided as the HCl salt. (vii)Vendor shall provide a final report with all the relevant results from the service rendered. (viii)The provision at FAR clause 52.212-1, Instructions to Offerors - Commercial Items, applies to this acquisition. (ix)The provision at FAR clause 52.212-2, Evaluation - Commercial Items applies to this acquisition. Selection of an Offeror for award will be on the basis of lowest price technically acceptable quote meeting the government's essential features as described herein. The offeror must include all specifications/services (including all brand-name or equal requirements so that the brand-name or equal status may be verified), detailed in this solicitation, in its quote. Offeror(s) cost/price proposal will be evaluated for reasonableness. For a price to be reasonable, it must represent a price to the Government that a prudent person would pay when consideration is given to prices in the market. Normally, price reasonableness is established through adequate price competition, but may also be determined through cost and price analysis techniques as described in FAR 15.404. (x)The provision at FAR clause 52.212-3, Offeror Representations and Certifications - Commercial Items, applies to this acquisition. (xi)FAR clause at 52.212-4, Contract Terms and Conditions - Commercial Items, applies to this acquisition. An addendum to FAR clause 52.212-4, Contract Terms and Conditions-Commercial Items applies to this acquisition. (xii)FAR clause at 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders-Commercial Items, applies to this acquisition. (xiii) There are no additional contract requirement(s) or terms and conditions (such as contract financing arrangements or warranty requirements) determined by the contracting officer to be necessary for this acquisition and consistent with customary commercial practices. (xiv)The Defense Priorities and Allocations System (DPAS) are not applicable to this requirement. (xv)Responses to this solicitation must include sufficient information to establish the interested parties' bona-fide capabilities of providing the product or service. In addition, responses must include clear and convincing evidence of the offeror's capability of fulfilling the requirement as it relates to the salient characteristics. The response should be practical, clear, and concise; should use quantitative terms whenever possible; should avoid qualitative adjectives; and should comprehensively address the requirements of this solicitation. Mandatory Criteria (Requirements) 1)Compound delivery: the compound will be received within 6 weeks of the purchase order being awarded or by 02/01/2016. 2)Specific services: The contactor shall provide the following services: a.Synthesis and delivery of 10.0 grams or more of ((7-bromo-6-chloro-3-(3-(4-chloro-3,5-dimethylphenoxy)propyl)-2-(trifluoromethyl)-1H-indole. b.Purity to exceed 95%. Appropriate documentation demonstrating these purity levels will be provided. Past Performance 3)The vendor shall demonstrate previous experience in the synthesis of compounds related to ((7-bromo-6-chloro-3-(3-(4-chloro-3,5-dimethylphenoxy)propyl)-2-(trifluoromethyl)-1H-indole, with appropriate analytical methods for the determination of its structure and purity. Assumptions, conditions, or exceptions with any of the terms and conditions of this solicitation must be noted. If not noted, the Government will assume that no assumptions, conditions, or exceptions are made and the offeror agrees to comply with all of the terms and conditions as set forth in the solicitation. Information requested herein must be furnished in writing fully and completely in compliance with the solicitation. The information requested and the manner of submittal is essential to permit prompt evaluation of all offers on a fair and uniform basis. Simple statements of compliance (i.e., "understood"; "will comply") or phrases such as "standard procedures will be used" or "well known techniques will be utilized" and other generalities, without the detailed description of how compliance will be met, may not be considered sufficient evidence that the proposal can technically meet the project requirements. Accordingly, any response in which material information requested is not furnished or where indirect or incomplete answers or information are provided may be considered not acceptable. In addition the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size must be included in the response. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov. All questions regarding this combined synopsis/solicitation must be received in this office by 8:00AM (EST) on January 13, 2016.. Offers must be received electronically by 12:00 PM (EST) on January 22, 2016. Facsimile submissions are not authorized and collect calls will not be accepted. Please reference the solicitation number HHS-NIH-NIDA-SSSA-CSS-2016-23 on your offer. (xvi)Requests for information concerning this requirement are to be addressed to Rodney Brooks via e-mail only to rodney.brooks@nih.gov prior to the closing date for questions. Submit offers to: Rodney Brooks, Contract Specialist at rodney.brooks@nih.gov and NIDASSSAPurchaseRequ@mail.nih.gov and the Contracting Officer Brian Lind at brian.lind@nih.gov.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NIDA-01/HHS-NIH-NIDA-SSSA-CSS-2016-23 /listing.html)
- Record
- SN03988304-W 20160113/160111234701-b450aef3d7fa1b9be1646efa5c89d617 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |